GLP-1 drugs have 'little or no effect' on risk of obesity-related cancers, study suggests

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...
Everyday Health on MSN

Quitting Zepbound Leads to at Least 25 Percent Weight Regain After a Year

Most people who stopped taking their weight loss injections also experienced negative changes in blood pressure, waist size, and other health metrics.
BioPharma Dive

Lilly’s three-pronged drug puts obesity field ‘on notice’

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Zealand Pharma seeks to challenge GLP‑1 dominance with obesity drug aimed at long‑term use

Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish company tries to break into the lucrative ...
Everyday Health on MSN

New Obesity Drug Helped People Lose Nearly One-Third Their Body Weight

The clinical trial showed this experimental medication to be much more effective than any existing GLP-1 drug. But that much ...
Drug Store News

Eli Lilly lowers price of Zepbound single-dose vials

With a valid prescription, patients can access the starting dose of Zepbound single-dose vial (2.5 mg) for as low as $299 per ...
BioPharma Dive

Prolynx banks $70M for longer-lasting obesity drugs

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...

Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

LLY leans on tirzepatide and a deep late-stage pipeline to defend its obesity momentum as new rivals make rapid progress in ...